TrialSignal
Clinical trial intelligence report
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06574360
Status
RECRUITING
Phase
Phase 2
Sponsor
China Medical University Hospital
Executive brief
Investment-Ready Snapshot
This clinical trial investigates the efficacy of a dual treatment approach combining a sigma-1 receptor agonist (S1RA) with an NMDA enhancer (NMDAE) for patients with treatment-resistant schizophrenia. The study aims to determine if this combination is more effective than S1RA alone, addressing a significant unmet need in schizophrenia treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06574360
Indication
Schizophrenia
Modality
small molecule
Target
Schizophrenia
Intervention
S1RA plus NMDAE, S1RA plus Placebo Cap
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.